Phase 3 Tuberculosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 60 years old
- People who weigh between 40 and 80 kilograms
- People who have been diagnosed with pulmonary (lung) tuberculosis that shows up on a sputum smear test and responds to the antibiotic rifampicin
- People who are willing to sign a consent form agreeing to take part (or, for younger participants, a parent's consent plus the participant's own agreement)
- Women who have not yet gone through menopause must agree to use effective birth control during the treatment period
Who may not be able to join:
- People whose tuberculosis has spread outside the lungs to other parts of the body
- People whose tuberculosis has caused very widespread lung damage (affecting more than 50% of the lungs) or large cavities in the lungs (larger than 4 cm)
- People whose tuberculosis bacteria are already known to be resistant to any of the following antibiotics: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones
- People who drink heavily — more than 64 grams of pure alcohol per day for men, or more than 42 grams per day for women
- People with a low red blood cell count (haemoglobin below 70g/L) or a low platelet count (below 100×10⁹/L)
- People with liver problems, including fluid on the abdomen, brain changes caused by liver disease, or certain abnormal liver blood test results
- People with kidney function that is significantly below normal, based on a blood creatinine level more than 1.5 times the upper normal limit
- People who have already received more than five days of treatment with certain tuberculosis or related antibiotics within the six months before the trial starts (confirm with trial site for the full list of medicines)
- People with a known history of a heart condition called prolonged QT syndrome, which affects the heart's electrical rhythm
- People currently taking, or planning to take within six months of joining, certain HIV medicines or specific heart-rhythm medicines (confirm with trial site for the full list of medicines)
- People with a known allergy or bad reaction to any of the medicines used in the trial
- People who have AIDS
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wenhong Zhang, PhD., Huashan Hospital of Fudan University，Shanghai，China
Phone: (086)15921403893
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment success rate of the short regimen during drug treatment and follow-up.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.